Patient Mental Health Outcomes in the Gout Management
It is impossible to meet the requirements of a community as a whole by developing the capacity to...
Read More
Meeting Coverage
What Drives Gout Racial Disparities in the USA?
Emerging data from US cohort studies imply that the costs of gout and hyperuricemia are...
Read More
Efficacy and Safety of ULT in CKD Patients With Gout
For the treatment of gout in chronic kidney disease CKD patients, there needs to be more...
Read More
Urate Deposition & Inflammation: Vasculature of Gout Patient
Hyperuricemia and the accompanying deposition of aggregated monosodium urate (MSU) crystals in...
Read More
MSU Crystal Volume for Pegloticase Plus MTX Patients
Reliable detection and measurement of monosodium urate (MSU) crystal deposits in gout patients can...
Read More
UA Consumption in the GI Tract with Escherichia coli Nissle
Gout, chronic kidney disease, type 2 diabetes, and cardiovascular disease are all linked to...
Read More
Pharmacokinetics & Immunogenicity of Pegloticase in KT Patients for Uncontrolled Gout
Pegloticase’s effectiveness is dramatically enhanced when immunomodulator co-therapy is used...
Read MoreCME Accreditation
The ECTRIMS 2022 – 38th Congress of the European Committee for Treatment and Research of Multiple Sclerosis, has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 18 European...
Read MoreWant to Go on an Intellectual Date at ECTRIMS?
This year at ECTRIMS you can go on a “date” with someone with the same research interests as you. Introducing Braindate, a service ECTRIMS is using to make it easy for attendees seeking expertise on key MS topics to...
Read MoreCME Accreditation
The ECTRIMS 2022 – 38th Congress of the European Committee for Treatment and Research of Multiple Sclerosis, has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 18 European...
Read MoreECTRIMS 2022: Why Attend?
Planning committees developed an interesting and diverse scientific program. Well-known session formats such as Scientific Sessions, Hot Topics or Meet the Experts are being brought back again this year The schedule also offers...
Read More
Brain Volume & Blood Lipids Changes in MS Patients
Changes in cholesterol metabolism may be linked to the progression of multiple sclerosis (MS)...
Read More
CSF Biomarkers of Early Worsening in PPMS
Active primary progressive multiple sclerosis (PPMS) has effective treatment options, thus...
Read More
Teriflunomide-treated mRNACOVID-19 MS Vaccine: Immunity
All multiple sclerosis (MS) patients should have the COVID-19 vaccine, as suggested by the...
Read More
Teriflunomide (TF) in Multiple Sclerosis Patients
For patients with relapsing-remitting multiple sclerosis (MS), teriflunomide (TF) is a...
Read More
TRL Dose in the MS Treatment After Cell Trafficking Therapy
Patients still face an increased risk of debilitating rebound illness within 6 months of drug...
Read More
Adjudicated Attack with Inebilizumab Vs. Aatralizumab
Recently, 3 innovative, safe, and effective biologic medicines for neuromyelitis optica spectrum...
Read More
B-Cell Subsets & Aquaporin-4 Antibody Titers with Disease Activity
Appropriate use of the anti-CD19 B-cell depleting antibody inebilizumab (INEB) in the treatment of...
Read More
Health-related Hardiness Education Program: NMOSD Patients
Health-related toughness is a personality trait that has the potential to mitigate the...
Read More
Interleukin 6 as a Blood Biomarker in NMOSD Patients
Demyelinating disease that primarily affects the spinal cord and optic nerve, neuromyelitis optica...
Read More